Degnan Chris
Chief Financial Officer
Degnan Chris has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Oct 9, 2026.
On the most recent filing, Degnan Chris is listed as Chief Financial Officer at UroGen Pharma Ltd. Inside the rolling window, Degnan Chris reported no open-market purchases and 1 open-market sale totaling $81K in URGN.
Companies traded
Other insiders at URGN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$81K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Oct 8, 2025 | URGN | Sale | $37K |
Frequently asked questions
How many SEC Form 4 filings has Degnan Chris made?
Degnan Chris has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Degnan Chris trade?
Degnan Chris has filed SEC Form 4 disclosures for 1 company, including URGN.
When was Degnan Chris's most recent SEC Form 4 filing?
Degnan Chris's most recent SEC Form 4 filing on Tracefour is dated Oct 9, 2026.
What is Degnan Chris's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Degnan Chris is listed as Chief Financial Officer.
What is Degnan Chris's total buy and sell value in the current window?
Inside the rolling retention window, Degnan Chris bought $0 and sold $81K based on SEC Form 4 filings.
What was Degnan Chris's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,202 URGN shares on 2026-10-08, worth $81K, per SEC Form 4 filings.